Roche Licenses Zymeworks DLL3 Trispecific T Cell Engager

Company Zymeworks; Roche Event Type Exclusive worldwide license Modality DLL3×CD3×CD28 trispecific T cell engager Asset ZW209 Target DLL3; CD3; CD28 Disease Area Small-cell lung cancer and neuroendocrine tumors Summary Zymeworks and Roche agreed on an exclusive worldwide license for ZW209, a DLL3×CD3×CD28 trispecific T cell…